The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation
- PMID: 24485002
- PMCID: PMC3923256
- DOI: 10.1186/1758-2946-6-5
The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation
Abstract
Background: In the European Union, medicines are authorised for some rare disease only if they are judged to be dissimilar to authorised orphan drugs for that disease. This paper describes the use of 2D fingerprints to show the extent of the relationship between computed levels of structural similarity for pairs of molecules and expert judgments of the similarities of those pairs. The resulting relationship can be used to provide input to the assessment of new active compounds for which orphan drug authorisation is being sought.
Results: 143 experts provided judgments of the similarity or dissimilarity of 100 pairs of drug-like molecules from the DrugBank 3.0 database. The similarities of these pairs were also computed using BCI, Daylight, ECFC4, ECFP4, MDL and Unity 2D fingerprints. Logistic regression analyses demonstrated a strong relationship between the human and computed similarity assessments, with the resulting regression models having significant predictive power in experiments using data from submissions of orphan drug medicines to the European Medicines Agency. The BCI fingerprints performed best overall on the DrugBank dataset while the BCI, Daylight, ECFP4 and Unity fingerprints performed comparably on the European Medicines Agency dataset.
Conclusions: Measures of structural similarity based on 2D fingerprints can provide a useful source of information for the assessment of orphan drug status by regulatory authorities.
Figures




Similar articles
-
Molecular Similarity Perception Based on Machine-Learning Models.Int J Mol Sci. 2022 May 30;23(11):6114. doi: 10.3390/ijms23116114. Int J Mol Sci. 2022. PMID: 35682792 Free PMC article.
-
Molecular similarity considerations in the licensing of orphan drugs.Drug Discov Today. 2017 Feb;22(2):377-381. doi: 10.1016/j.drudis.2016.11.024. Epub 2016 Dec 10. Drug Discov Today. 2017. PMID: 27965161 Review.
-
Effectiveness of graph-based and fingerprint-based similarity measures for virtual screening of 2D chemical structure databases.J Comput Aided Mol Des. 2002 Jan;16(1):59-71. doi: 10.1023/a:1016387816342. J Comput Aided Mol Des. 2002. PMID: 12197666
-
Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance.J Chem Inf Comput Sci. 2004 Sep-Oct;44(5):1708-18. doi: 10.1021/ci0498719. J Chem Inf Comput Sci. 2004. PMID: 15446830
-
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].Z Evid Fortbild Qual Gesundhwes. 2013;107(2):120-8. doi: 10.1016/j.zefq.2013.02.003. Epub 2013 Apr 4. Z Evid Fortbild Qual Gesundhwes. 2013. PMID: 23663906 Review. German.
Cited by
-
Comparing structural fingerprints using a literature-based similarity benchmark.J Cheminform. 2016 Jul 5;8:36. doi: 10.1186/s13321-016-0148-0. eCollection 2016. J Cheminform. 2016. PMID: 27382417 Free PMC article.
-
Chemoinformatics in the New Era: From Molecular Dynamics to Systems Dynamics.Molecules. 2016 Mar 3;21(3):71. doi: 10.3390/molecules21030071. Molecules. 2016. PMID: 26950111 Free PMC article.
-
Analysis of the effects of related fingerprints on molecular similarity using an eigenvalue entropy approach.J Cheminform. 2021 Mar 23;13(1):27. doi: 10.1186/s13321-021-00506-2. J Cheminform. 2021. PMID: 33757582 Free PMC article.
-
Can human experts predict solubility better than computers?J Cheminform. 2017 Dec 13;9(1):63. doi: 10.1186/s13321-017-0250-y. J Cheminform. 2017. PMID: 29238891 Free PMC article.
-
Molecular Similarity Perception Based on Machine-Learning Models.Int J Mol Sci. 2022 May 30;23(11):6114. doi: 10.3390/ijms23116114. Int J Mol Sci. 2022. PMID: 35682792 Free PMC article.
References
-
- Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N’Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Matulevičiene A, Metz H. et al.European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10:341–349. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources